Skip to main content
. 2019 Jul 9;105(6):1630–1640. doi: 10.3324/haematol.2019.218289

Figure 2.

Figure 2.

DARS-AS1 participates in proliferation and inhibits apoptosis of myeloma cells in a hypoxic environment. (A, B) Cell growth of RPMI 8226 and LP-1 cells with DARS-AS1 knockdown in a hypoxic environment was determined every 24 h for 72 h using an automated cell counter (Countstar). (C, D) Cell growth of RPMI 8226 and LP-1 cells with DARS-AS1 overexpression was determined every day for 7 days using an automated cell counter (Countstar). (E) The rates of annexin V+ cells in myeloma cells with DARS-AS1 knockdown and control cells were determined by flow cytometry. (F) Cleaved caspase-3 and cleaved PARP were demonstrated by western blotting of RPMI 8226 and LP-1 cells with DARS-AS1 knockdown. (G, I) Xenograft mouse models of myeloma cells with DARS-AS1 overexpression or DARS-AS1 knockdown in NOD-SCID mice. (H, J) Ki67 staining of xenografts of DARS-AS1 overexpressing or DARS-AS1 knockdown cells.*P<0.05 and **P<0.01, compared with the control. Data are presented as the mean ± standard error of mean from three experiments.